[Unrelated donor peripheral blood stem cell transplantation for hematologic malignancies].
This study was aimed to explore feasibility and efficacy of unrelated donor peripheral blood stem cell transplantation (UD-PBSCT) in treatment of hematologic malignancies. Ten patients with hematologic malignancies underwent high resolution DNA based typing HLA-matched or 1 locus mismatched UD-PBSCT. Busulfan, cyclophosphamide, Ara-C, MeCCNU and antithymocyte globulin (ATG) were used for preconditioning regimen in all cases. All patients received mycophenolate mofetile, cyclosporin A and short-term methotrexate with CD25 antibody as the graft-versus-host disease (GVHD) prophylaxis. The results showed that rapid engraftment was observed in all cases who presented full donor chimerism at 28 days post transplantation by STR-PCR. The median time of neutrophil recovery > 0.5 x 10(9)/L, platelet recovery > 20 x 10(9)/L was 13, 17.5 days respectively after transplantation. The incidence of acute GVHD was 3 cases (one case with grade I was recovered from GVHD by himself, one case with grade III was cured, one case with grade VI was died). It is concluded that above-mentioned preconditioning regimen and GVHD prophylaxis are effective approaches for unrelated donor peripheral blood stem cell transplantation in hematopoietic malignancies.
Department of Hematology, General Hospital of China PLA, Beijing 100853, China. gaochunji@hotmail.com
Chun-Ji
CJ
Gao
Wan-Ming
WM
DA
Bo-Long
BL
Zhang
Xiao-Ping
XP
Han
Yu
Y
Jing
Hong-Hua
HH
Li
Jian
J
Bo
Hai-Yan
HY
Zhu
Hai-Jie
HJ
Jin
Xiao-Xiong
XX
Wu
Quan-Xun
QX
Wang
Su-Sia
SS
Li
Wen-Rong
WR
Huang
Li
L
Yu
D000293:Adolescent; D000328:Adult; D001782:Blood Donors; D005260:Female; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006801:Humans; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation / Q000379:methods; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000628:therapy*